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Abstract
Overweight and obesity among children and adolescents continue to 
be a global public health epidemic. Current national data on child-
hood and adolescent obesity show alarming statistics of overweight 
and obese children and adolescents. This epidemic runs across vari-
ous continents and affects various ethnic populations. The current 
weight management practices involve dietary modification, behav-
ioral change therapies involving exercise, pharmacological therapy 
and surgical intervention. The purpose of this current review is to 
focus on pharmacological therapy i.e. role of sibutramine and or-
listat in childhood and adolescent weight management.  An open 
search of PUBMED database was made with search ‘key words’ 
such as ‘orlistat’ or ‘sibutramine’ or “pharmacological approaches” 
and “child obesity” and “adolescent obesity”. This yielded a total of 
20 articles. All of these articles have been summarized in the current 
review. Sibutramine functions by promoting satiety and increases 
energy  expenditure  by  inhibiting  reuptake  of  noradrenaline  and 
serotonin. Most of the studies, reviews and trials conducted using 
sibutramine among adolescents and children show limited short-
term efficacy. The long-term effects of sibutramine use are not yet 
studied due to the severity of its side-effects profile. Orlistat was 
approved by Food and Drug Administration for adolescent weight 
reduction. Despite its approval, it has a limited role in adolescent 
and pediatric obesity reduction due to the purported malabsorp-
tion of fat soluble vitamins and its side-effect profile. Obesity and 
adolescent weight management in present times mainly deals with 
dietary modification with superadded behavioral therapies promot-
ing exercise. There is insufficient evidence as of now if these alone 
would cause adequate weight reduction and weight maintenance. 
Pharmacotherapy i.e use of drugs like sibutramine and orlistat has 
a limited role in the current fight against childhood and adolescent 
obesity. Extreme side-effects, close monitoring and lack of long-
term studies involving these drugs, suggest questionable efficacy 
in current times. Future research studies involving pharmacological 
agents need to not only have immense scientific rigor during pre-
liminary analyses but should also translate their efficacy in practical 
and clinical settings.
Keywords:  Obesity; Overweight; Adolescents; Pharmacological; 
sibutramine; Orlistat
Introduction
Overweight  and  obesity  continue  to  cause  public  health 
crisis in the United States. The recent National Health and 
Nutrition Examination Survey (NHANES) data reflects it to 
be quite a significant burden with 16.3% of all children be-
tween the ages of 2 to 12 years being found obese and 31.9% 
found to be overweight [1].  The rates in adolescents showed 
a worse picture with 17.6% being obese and 34.1% over-
weight. Further stratification of this data as per gender, ado-
lescent males had the highest prevalence of overweight and 
obesity among all age groups, with 18.2% male and 16.2% 
female being obese and 33.3% female and 34.9% male be-
ing  overweight.  Overweight  and  obesity  issues  pervades 
across different ethnic groups such that non-Hispanic blacks 
(22.9%) adolescents have a higher reported prevalence when 
compared  to  non-Hispanic  white  adolescents  (16%)  [1]. 
The obesity and overweight epidemic though on rise in the 
United States doesn’t exclude countries worldwide.  In 2003, 
23.5% Eastern Mediterranean, 25.5% European and 10.6% 
of South East Asian children and adolescents were reported 
either overweight or obese [2].
In the United States, obesity estimates among adoles-
cents are often based on body mass index (BMI) percentile 
scores, which the International Obesity Task Force accepts 
as a valid method for measuring body composition. A recent 
meta-analysis of school-based obesity interventions howev-
er concluded that BMI may not be a modifiable outcome [3]. 
Adolescent body fat composition can be measured by triceps 
and sub scapular skin fold thickness. Investigators reported 
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that child and adolescent body fatness has increased 0.9% 
per decade since the 1950s and in 2003, the average percent-
age of body fat for child and adolescent boys and girls were 
16.2% and 22.2% respectively [4]. 
There are four modalities for current management of 
adolescent overweight and obesity: dietary management, in-
creasing physical activity, pharmacological therapy and bar-
iatric surgery [5, 6, 7, 8]. The purpose of the current article 
is to review current pharmacotherapies for management of 
child and adolescent obesity.
Role of Pharmacotherapy
In the United States, the Food and Drug Administration has 
approved two drugs for pharmacological therapy [7], these 
are orlistat and sibutramine. Orlistat blocks absorption of 
fat in the intestines by decreasing action of lipase and as a 
result creates negative energy balance. The main adverse ef-
fects associated with its use are malabsorption of fat soluble 
vitamins and oily stools. Sibutramine promotes satiety and 
increases energy expenditure by inhibiting reuptake of nor-
adrenaline and serotonin. Sibutramine also causes anorexia. 
Side-effects of sibutramine include palpitations, high blood 
pressure and headaches.
Methodology
The current review addresses role of orlistat and sibutra-
mine as pharmacological interventions for management of 
child and adolescent obesity. The search methodology used 
PUBMED database with a Boolean search strategy including 
years 2007-2010. The key words of “orlistat”, or “sibutra-
mine” or “pharmacological approaches” and “child obesity” 
and “adolescent obesity” were used. This yielded a total of 
20 articles, Table 1. Results of the current pharmacological 
trials, interventions, concepts and adverse effects of these 
two important drugs are summarized in the results section. 
Role of Sibutramine 
Sibutramine which was approved in 1998 has been widely 
evaluated in various trials since its approval. Among various 
placebo-controlled trials ranging from 16 - 52 weeks weight 
loss varied from 3.4 to 6 kilograms [9]. A large multicentered 
randomized trial from Sibutramine adolescent study group 
proved the drugs efficacy at par with previous studies includ-
ing adults in decreasing adolescent BMI. Efficacy of sibutra-
mine is also proven when it came to decrease in body weight, 
binge eating episodes and psychiatric symptoms. So there 
is emerging evidence that sibutramine can be a valid thera-
peutic option for obese adolescents. The only caveat being 
regular monitoring of blood pressure and pulse rates, though 
preliminary  trials  are  reporting  its  safety  and  tolerability 
[10,  11].  In  a  double-blind  placebo-controlled  cross-over 
study conducted among children diagnosed with hypotha-
lamic obesity, sibutramine was found to be efficacious [12]. 
This study may provide window of opportunities for using 
sibutramine in syndromic obesity in future.  
Various studies discussing the role of sibutramine along 
with behavior therapy have shown successful results in obe-
sity reduction [11]. As safety issues related to sibutramine 
therapy are still under investigation, trials conducted using 
intermittent therapies versus continuous therapy have a spe-
cial role in obesity management. Intermittent therapy has 
shown  similar  efficacy  to  continuous  drug  administration 
[13]. 
Role of Orlistat
The role of orlistat in adolescent overweight management is 
limited by the Food and Drug Administration for adolescents 
aged 12-18 years old and having BMI more than 2 units 
above the 95th percentile for the age and gender. A one year 
placebo-controlled trial where orlistat was used along with 
a hypo-caloric diet, exercise and behavior therapy showed 
a significant decrease in BMI along obese American adoles-
cents [6]. The use of orlistat in pediatric patients is limited 
due to the severe side-effects such as fatty or oily stools 
along with a risk of possible malabsorption of fat soluble 
vitamins [6, 14]. Binge eating, a psychiatric condition lead-
ing to obesity has also been managed by using orlistat [15].
Combined Trials: Sibutramine and Orlistat
The  pharmacologic  literature  on  the  combination  therapy 
of sibutramine with orlistat has shown great promise. In the 
first trial to assess efficacy of this combination, the patients 
were only randomized to added orlistat or placebo after a 
previous weight loss period with sibutramine alone. Addi-
tion of orlistat did not help in further weight loss that what 
was achieved with sibutramine alone [10]. Similarly, another 
randomized open-labeled short term trial failed to show any 
significant difference between the sibutramine only group 
and the combination (sibutramine + orlistat) group on de-
crease in BMI [16].  
In a recent meta-analysis which included a total of eight 
trials (5 sibutramine and 3 orlistat), it was seen that there was 
a mean decrease in weight of 5.25 kilograms after a mini-
mum follow-up period of 6 months [17]. In a study which 
tried to address whether there are any psychological corre-
lates of combined drug therapy, it was concluded that sibutra-
mine exerted its greatest effect in patients whose eating is a 
natural response to hunger than regulated by cognitions and 
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conscious controls. Personality attribute of conscientious-
ness was important as orlistat needs good pharmacological 
adherence [18]. Thus we see that a combined pharmacologi-
cal approach is affected by many extraneous factors such as 
personality and psychological characteristics of the persons 
involved. 
Most of the literature which looks at a combined effect 
of sibutramine and olistat has found no additional benefit of 
adding orlistat in causing weight reduction in overweight ad-
olescents. In a Cochrane review of 64 randomized-controlled 
trials, 10 studies focused on pharmacologic management of 
childhood obesity. The results concluded that pertaining to 
childhood obesity either sibutramine or orlistat can be used 
as an adjunct to life-style interventions. Side-effects of these 
drugs however should be carefully monitored [19]. Similarly 
a meta-analysis of 17 pharmacological interventions showed 
a large pooled effect size with a consistent loss in body mass 
index of 2.4 kg/m2 of sibutramine use in adolescent obesity 
reduction after 6 months of usage. While for orlistat, the re-
duction in BMI was 0.7 kg/m2, a small to moderate effect. 
This meta-analytic study reaffirms the earlier studies [28] 
in explicating short-term efficacy of both these drugs. The 
study of long term efficacy of these drugs continues to be 
a challenge among researchers, as the side-effect profile of 
these drugs precludes these designs.
Discussion
Obesity  and  overweight  management,  particularly  among 
adolescents and children continues to be a great challenge. 
The current management arsenal in the fight against obesity 
consists of dietary therapy, pharmacologic therapy and surgi-
cal intervention. The current review, focusing on two drugs 
sibutramine and orlistat, offers a panoramic view of the vari-
ous trials and studies conducted till date. Though orlistat is 
approved to be used in adolescents, its use in pediatric popu-
lation is associated with lot of problems such as fat malab-
sorption since it interferes with child growth. Similarly in 
adolescents the side-effect profile of this drug needs to be 
studied in details in long-term trials [20]. The results of the 
meta-analytic studies and placebo-controlled trials conduct-
ed till date give credence to the limited use of these drugs in 
adolescent obesity reduction. Studies which have shown use-
fulness of these drugs have either been short-term studies or 
have tried these pharmacological agents as an add-on treat-
ment. The important questions to ask ourselves, as research-
ers, are what are the options we are having for childhood and 
adolescent obesity management? Dietary modifications and 
behavior therapies need a lot of parental input in terms of 
time and effort and weight-loss supplements make dubious 
claims of efficacy as often advertised [21]. Surgical interven-
tion, bariatric surgery, is restricted to morbidly obese ado-
lescents and is not a blanket option [22, 23]. This leaves us 
little choice in choosing an appropriate management strategy 
which is sustainable over time.
In conclusion, childhood obesity related pharmacologi-
cal treatment has greatly increased in the past 8 years. The 
majority of these drugs including sibutramine and orlistat are 
rapidly discontinued before patients (children) can see the 
weight benefits [24]. This, itself is an evidence that drugs 
which have been having limited efficacy in adult population 
need to be used with greater scientific rigor and supervision 
in adolescent efficacy trials. Hence, in the light of the avail-
able evidence, it would be advisable and recommended to 
use these two drugs (sibutramine and orlistat) with caution 
and careful monitoring of side-effects. Current existing sys-
tematic reviews [25, 26] conclude a very limited short-term 
efficacy of these drugs and that too when they are added to 
the existing behavioral interventions. The need for long term 
efficacy trials and replication of current study protocols in 
future, cannot be overemphasized.
Implications for Practice
It is very important to understand that adolescent obesity 
or overweight may be linked to multiple causes or having 
various associations such as hypothalamic obesity, binge eat-
ing disorders, anorexia nervosa and bulimia. The outcome 
of lifestyle interventions such as dietary modifications, in-
creased  physical  activity  and  weight-loss  supplements  in 
obesity reduction is insufficient in present times. Pharmaco-
logical therapy holds promise for future in the form of drugs 
like sibutramine, orlistat and metformin. From the current 
practical standpoint, orlistat is the only FDA approved drug 
to be used in adolescents and its long-term effects are still 
questionable.  Sibutramine,  though  used  judiciously  as  an 
adult drug still needs to be accepted as a pediatric and an 
adolescent treatment drug due to its severe side-effects. Also 
long-term efficacy of this drug in consistent weight reduction 
needs to be studied in various adolescent populations with 
different dosages [27]. Future pharmacological studies in-
volving sibutramine and orlistat will hold a definitive prom-
ise if researchers devise an altered molecular structure drug 
producing better tolerability and longer effect sustainability.
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